During the median follow-up period of 17.7 months, the median PFS of Sotorasib treatment is 5.6 months (95% CI: 4.3–7.8 months), while the median PFS of docetaxel is 4.5 months (95% IC: 3.0–5.7 months) in NSCLC patients with a K-Ras G12C mutation [75]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.